Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD5 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD5 ECD-Fc Fusion Protein / Mutant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View CD5 Products |
| Gene Delivery | CD5 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. Essential for CAR-T co-culture assays and internalization assays. | View CD5 Products |
| Benchmark Ab | Anti-CD5 (Benchmark Positive Control / Sequence of Reference Antibodies). Recombinant monoclonal antibody for assay validation, affinity benchmarking and binding qualification. | View CD5 Products |
| Validator | CD5 siRNA Set. For knockdown verification, fratricide-resistance screening, and specificity control in cell-based assays. | View CD5 Products |
| CD6 | CD6. Closely related SRCR superfamily member; essential for CD5 off-target/counter-screening panels. | View CD6 Products |
| CD7 | CD7. Synergistic target for dual CAR-T therapies in T-ALL. | View CD7 Products |
| CD3E | CD3E. T-cell co-receptor complex component; synergistic context for T-cell directed combination strategies and bispecific antibody development. | View CD3E Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog CD5 ECD proteins available with >95% purity; sequence verified by mass spec. |
| CD6 subfamily counter-screening | Homolog panel (CD5/CD6) proteins strictly verified by mass spec to ensure selectivity assay rigor. |
| Internalization & ADC payload delivery | HEK293-expressed CD5 ECD-Fc preserves native glycosylation patterns required for conformational internalization assays. Human/Cyno ortholog ECD-Fc proteins available with >95% purity. |
| T-cell fratricide resistance (CAR-T) | Full-length CD5 lentivirus for stable reporter cell lines; enables fratricide evaluation and knockdown rescue. High-efficiency Lentivirus for stable CD5 target cell line generation; validated siRNA for endogenous CD5 silencing controls. |
| Lack of Reliable Controls | Recombinant benchmark antibody (including clinical benchmark antibodies/biosimilars) included for positive control and affinity benchmarking. |
| False Positives in Flow Cytometry | Endotoxin Controlled (<1 EU/µg) reagents ensuring no non-specific immune cell activation during assays. |
| Assay Standardization | Recombinant benchmark antibody included for positive control. |
| Specificity Verification | Sequence-verified siRNA included for knockdown specificity checks. |
Live CD5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD5 therapeutics is intensifying, driven by the unmet clinical need in relapsed/refractory T-cell malignancies (T-ALL, Peripheral T-Cell Lymphomas, CTCL). While traditional mAbs paved the way, developers are shifting focus from naked antibodies to CAR-T cell therapies and ADCs. The next wave of R&D is targeting the "fratricide" challenge—since normal T-cells and CAR-T cells themselves express CD5, next-generation therapies require sophisticated genomic editing (e.g., CD5 knockout CAR-T cells) or specialized intracellular retention domains. Furthermore, CD5 is emerging as a compelling target for severe autoimmune diseases due to its role in regulating T-cell receptor (TCR) signaling. As first-generation T-cell engaging programs address fratricide challenges, the next wave of R&D is targeting autoimmune indications and refractory T-cell malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Emerging biotech & academic consortiums | T-cell malignancies, CLL, Refractory T-Cell Lymphomas | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| CAR-T (Autologous / Allogeneic) | Baylor College of Medicine, Gracell Biotechnologies, iCell Gene Therapeutics, academic medical centers | T-ALL, CTCL, PTCL, r/r lymphoma | Fratricide/Expression Assay (Need full-length lentivirus stable cell lines & KO validation tools) |
| Monoclonal Antibody | Autoimmune-focused biopharma, traditional pipelines | Transplant rejection, SLE, Autoimmune Disorders, GvHD | Cross-reactivity & Selectivity, Receptor Occupancy/Affinity Assays (Need ortholog/homolog protein panels and endotoxin-free ECD proteins) |
| Bispecific | Immuno-oncology innovators, various preclinical pipelines | Resistant hematologic tumors, T-cell Malignancies | Heterodimer Validation & T-cell activation (Need CD5/CD3 co-assay reagents and pure proteins) |